Close Menu

NEW YORK — OpGen on Thursday reported a 54 percent increase in preliminary third quarter revenues as it consolidates its product portfolio following its acquisition of German diagnostics firm Curetis earlier this year.

For the three-month period ended September 30, OpGen expects revenues of $1.0 million versus $648,000 in the same quarter a year ago. The Gaithersburg, Maryland-based firm finished the third quarter with $10.4 million in cash.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.